| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Graphite Bio Inc. Common Stock (NASDAQ: GRPH)
GRPH Technical Analysis
5
| As on 9th Jun 2023 GRPH STOCK Price closed @ 2.84 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 5.26 & Strong Sell for SHORT-TERM with Stoploss of 10.17 we also expect STOCK to react on Following IMPORTANT LEVELS. |
GRPHSTOCK Price
| Open | 2.96 | Change | Price | % |
| High | 3.01 | 1 Day | -0.12 | -4.05 |
| Low | 2.84 | 1 Week | 0.17 | 6.37 |
| Close | 2.84 | 1 Month | 0.02 | 0.71 |
| Volume | 50300 | 1 Year | -8.18 | -74.23 |
| 52 Week High 13.06 | 52 Week Low 1.85 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| GRPH Daily Charts |
GRPH Intraday Charts |
Whats New @ Bazaartrend |
GRPH Free Analysis |
|
|
GRPH Important Levels Intraday
| RESISTANCE | 3.17 |
| RESISTANCE | 3.06 |
| RESISTANCE | 3.00 |
| RESISTANCE | 2.93 |
| SUPPORT | 2.75 |
| SUPPORT | 2.68 |
| SUPPORT | 2.62 |
| SUPPORT | 2.51 |
GRPH Forecast April 2024
| 4th UP Forecast | 14.02 |
| 3rd UP Forecast | 10.43 |
| 2nd UP Forecast | 8.22 |
| 1st UP Forecast | 6 |
| 1st DOWN Forecast | -0.32 |
| 2nd DOWN Forecast | -2.54 |
| 3rd DOWN Forecast | -4.75 |
| 4th DOWN Forecast | -8.34 |
GRPH Weekly Forecast
| 4th UP Forecast | 6.52 |
| 3rd UP Forecast | 5.34 |
| 2nd UP Forecast | 4.61 |
| 1st UP Forecast | 3.88 |
| 1st DOWN Forecast | 1.80 |
| 2nd DOWN Forecast | 1.07 |
| 3rd DOWN Forecast | 0.34 |
| 4th DOWN Forecast | -0.84 |
GRPH Forecast2024
| 4th UP Forecast | 25.58 |
| 3rd UP Forecast | 18.29 |
| 2nd UP Forecast | 13.78 |
| 1st UP Forecast | 9.27 |
| 1st DOWN Forecast | -3.59 |
| 2nd DOWN Forecast | -8.1 |
| 3rd DOWN Forecast | -12.61 |
| 4th DOWN Forecast | -19.9 |
Graphite Bio Inc. Common Stock ( NASDAQ USA Symbol : GRPH )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
GRPH Business Profile
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Address: 279 East Grand Avenue, South San Francisco, CA, United States, 94080
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service